Next Article in Journal
Assessment of Nonnucleoside Inhibitors Binding to HIV-1 Reverse Transcriptase Using HYDE Scoring
Next Article in Special Issue
Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases
Previous Article in Journal / Special Issue
Long-Acting Anti-HIV Drugs Targeting HIV-1 Reverse Transcriptase and Integrase
Open AccessBrief Report

Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines

1
Laboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal
2
CIIMAR, Interdisciplinary Centre of Marine and Environmental Research, University of Porto, Terminal de Cruzeiros do Porto de Leixões, Avenida General Norton de Matos P, 4450-208 Matosinhos, Portugal
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2019, 12(2), 63; https://doi.org/10.3390/ph12020063
Received: 10 March 2019 / Revised: 16 April 2019 / Accepted: 18 April 2019 / Published: 21 April 2019
(This article belongs to the Special Issue The Story of Successful Drugs and Recent FDA-Approved Molecules)
Omadacycline (Nuzyra®) is a new aminomethylcycline, approved by the U. S. Food and Drug Administration in 2018, as a tetracycline antibacterial. It can be used in community-acquired pneumonia and in acute bacterial skin and skin-structure infections. It was developed and is commercialized by Paratek Pharmaceuticals. It is a semisynthetic compound, derived from minocycline, capable of evading widely distributed efflux and target protection antibacterial resistance mechanisms and has demonstrated activity in a broad spectrum of bacteria. View Full-Text
Keywords: Omadacycline; aminomethylcycline; tetracycline; antibacterial; protein synthesis inhibitor; FDA approved Omadacycline; aminomethylcycline; tetracycline; antibacterial; protein synthesis inhibitor; FDA approved
Show Figures

Figure 1

MDPI and ACS Style

Durães, F.; Sousa, E. Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines. Pharmaceuticals 2019, 12, 63.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop